To Evaluate the Clinical Efficacy of Probiotic in Patients with DKD

Status: Recruiting
Location: See location...
Intervention Type: Dietary supplement, Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

To evaluate the efficacy of probiotics in the treatment of diabetic kidney disease, this study is designed to explore after consumption of probiotics lactobacillus reuteri ADR-1 and lactobacillus rhamnosus GM-020 composite strain powder sachets for 6 months, whether the improvement of blood sugar, kidney related indicators can further improve the course of diabetic kidney disease. The clinical trial predicted that probiotics can improve diabetic kidney disease by changing the intestinal flora by inhibiting harmful bacteria, reduction of systemic oxidative stress, balance carbohydrate and fat metabolism, further preventing the progress of diabetic kidney disease.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 25
Maximum Age: 80
Healthy Volunteers: f
View:

• Age between 25 and 80 years old

• Suffering from type 2 diabetes and stable medication for 3 months

• Detection of HbA1c before meals between 7% and 10%

• Stage 1-3a diabetic nephropathies (eGFR \> 45 mL/min)

• Microalbuminuria estimated between 30 to 300 mg/day

Locations
Other Locations
Taiwan
Chung Shan Medical University Hospital
RECRUITING
Taichung
Contact Information
Primary
Fang-Kuei Lin, Master
meitung@genmont.com.tw
+886-6-505-2151
Backup
Wan-Hua Tsai, PhD
twh@genmont.com.tw
+886-6-505-2151
Time Frame
Start Date: 2023-04-24
Estimated Completion Date: 2025-02-28
Participants
Target number of participants: 50
Treatments
Experimental: Probiotic group
Subjects received two probiotic sachets per day
Placebo_comparator: Placebo group
Subjects received two placebo sachets per day
Related Therapeutic Areas
Sponsors
Collaborators: Chung Shan Medical University
Leads: GenMont Biotech Incorporation

This content was sourced from clinicaltrials.gov